quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator
Company profile
Ticker
DGX
Exchange
Website
CEO
Stephen Rusckowski
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Laboratory Corp. Of America • Fortrea • Radnet • Akumin • Burning Rock Biotech • Guardant Health • Genomic Health • Exact Sciences • Invitae • Natera ...
Former names
CORNING CLINICAL LABORATORIES INC
SEC CIK
Corporate docs
Subsidiaries
100% Quest Diagnostics Holdings Incorporated • 100% Quest Diagnostics International Holdings Limited • 100% Quest Diagnostics Holdings Ltd. • 100% ExamOne Canada, Inc. • 99.9% Quest Diagnostics HTAS India Private Limited • 100% Quest Diagnostics of Puerto Rico, Inc. • 100% Quest Diagnostics Ireland Limited • 100% Quest Diagnostics (Shanghai) Co., Ltd. • 100% Quest Diagnostics Clinical Laboratories, Inc. • Solstas Lab Partners Group ...
IRS number
161387862
DGX stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
25 Mar 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
1 Feb 24
8-K
Quest Diagnostics Prices $750 Million of Senior Notes
1 Nov 23
424B2
Prospectus for primary offering
31 Oct 23
FWP
Free writing prospectus
30 Oct 23
424B2
Prospectus for primary offering
30 Oct 23
S-8
Registration of securities for employees
27 Oct 23
10-Q
2023 Q3
Quarterly report
25 Oct 23
8-K
Updates Guidance for Full Year 2023
24 Oct 23
Transcripts
DGX
Earnings call transcript
2023 Q4
1 Feb 24
DGX
Earnings call transcript
2023 Q3
24 Oct 23
DGX
Earnings call transcript
2023 Q2
26 Jul 23
DGX
Earnings call transcript
2023 Q2
26 Jul 23
DGX
Earnings call transcript
2023 Q1
27 Apr 23
DGX
Earnings call transcript
2022 Q4
2 Feb 23
DGX
Earnings call transcript
2022 Q3
20 Oct 22
DGX
Earnings call transcript
2022 Q2
21 Jul 22
DGX
Earnings call transcript
2022 Q1
21 Apr 22
DGX
Earnings call transcript
2021 Q4
4 Feb 22
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 143.00 mm | 143.00 mm | 143.00 mm | 143.00 mm | 143.00 mm | 143.00 mm |
Cash burn (monthly) | (no burn) | 46.42 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 277.83 mm | n/a | n/a | n/a | n/a |
Cash remaining | n/a | -134.83 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | -2.9 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
87.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 774 |
Opened positions | 78 |
Closed positions | 87 |
Increased positions | 221 |
Reduced positions | 321 |
13F shares | Current |
---|---|
Total value | 11.78 tn |
Total shares | 96.66 mm |
Total puts | 285.70 k |
Total calls | 936.30 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 13.62 mm | $1.66 tn |
BLK Blackrock | 11.39 mm | $1.39 tn |
STT State Street | 5.34 mm | $650.90 bn |
American Century Companies | 3.55 mm | $433.15 bn |
Victory Capital Management | 3.41 mm | $416.09 bn |
Wellington Management | 2.61 mm | $318.52 bn |
Geode Capital Management | 2.47 mm | $300.78 bn |
T. Rowe Price | 2.21 mm | $269.46 bn |
JPM JPMorgan Chase & Co. | 2.00 mm | $243.88 bn |
Dimensional Fund Advisors | 1.97 mm | $240.44 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Feb 24 | Michael E Prevoznik | Common Stock | Sell | Dispose S | No | Yes | 125.88 | 5,611 | 706.31 k | 38,478 |
29 Feb 24 | Catherine T. Doherty | Common Stock | Sell | Dispose S | No | Yes | 125.88 | 1,187 | 149.42 k | 68,412 |
28 Feb 24 | Deppe Michael J | Common Stock | Payment of exercise | Dispose F | No | No | 126.36 | 57 | 7.20 k | 34,930 |
28 Feb 24 | Deppe Michael J | Common Stock | Payment of exercise | Dispose F | No | No | 126.36 | 52 | 6.57 k | 34,987 |
28 Feb 24 | J. E. Davis | Common Stock | Payment of exercise | Dispose F | No | No | 126.36 | 1,804 | 227.95 k | 125,968 |
28 Feb 24 | J. E. Davis | Common Stock | Payment of exercise | Dispose F | No | No | 126.36 | 3,216 | 406.37 k | 127,772 |
28 Feb 24 | Karthik Kuppusamy | Common Stock | Payment of exercise | Dispose F | No | No | 126.36 | 68 | 8.59 k | 15,124 |
28 Feb 24 | Karthik Kuppusamy | Common Stock | Payment of exercise | Dispose F | No | No | 126.36 | 205 | 25.90 k | 15,192 |
28 Feb 24 | Michael E Prevoznik | Common Stock | Payment of exercise | Dispose F | No | No | 126.36 | 456 | 57.62 k | 44,089 |
28 Feb 24 | Michael E Prevoznik | Common Stock | Payment of exercise | Dispose F | No | No | 126.36 | 405 | 51.18 k | 44,545 |
News
Key Takeaways From Quest Diagnostics Analyst Ratings
20 Mar 24
Truist Securities Reiterates Hold on Quest Diagnostics, Maintains $145 Price Target
20 Mar 24
AMC Entertainment Tops The List Of High-Yielding Corporate Bonds — A Look At Yields As Bond Appetites Grow
18 Mar 24
(DGX) - Analyzing Quest Diagnostics's Short Interest
5 Mar 24
Breaking Down Quest Diagnostics: 7 Analysts Share Their Views
26 Feb 24
Press releases
Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
26 Mar 24
Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024
19 Mar 24
Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference
23 Feb 24
Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery
21 Feb 24
Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection
15 Feb 24